Julio Chavez, MD, MD, discussed treatment options for LBCL after relapsing on CAR T-cell therapy.
Targeted Oncology Staff
Advertisement
Articles by Targeted Oncology Staff
Experts discussed challenges with treating relapsed or refractory diffuse large B-cell lymphoma.
Experts discussed treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.
Early safety and efficacy data support the use of natural killer T (NKT) cells in patients with stage IV relapsed/refractory neuroblastoma.
Advertisement
Latest Updated Articles
Uptake of Nononcology Gene Therapy Remains Slow in HematologyPublished: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLDPublished: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 DataPublished: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell TherapyPublished: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMDPublished: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of VisionPublished: May 18th 2023 | Updated:
Advertisement
Advertisement
